Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Werewolf Therapeutics is raising $72,069,999.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Dan Hicklin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Werewolf Therapeutics

Immunotherapy represents one of the greatest advances for people living with cancer, but off-target effects remain a challenge in the clinical setting. Our technology is designed to unleash validated and proven proinflammatory mechanisms on tumors while preventing unwanted side effects on non-target tissue. We create systemically delivered targeted therapies that address the limitations of immuno-oncology. Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies.

To learn more about Werewolf Therapeutics, visit http://werewolftx.com/

Contact:
Dan Hicklin, President and Chief Executive Officer
617-952-0555

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved